Optimizing Clinical Use of Biomarkers in High-Risk Acute Heart Failure Patients
Why the study?
Does a multimarker, multi-time-point model improve prediction of post-discharge clinical outcomes in high-risk acute heart failure patients?
Population
2033 high-risk patients with acute heart failure (AHF) enrolled in the PROTECT trial
Comparison
Multimarker model combining blood urea nitrogen… vs Single biomarkers at single time-points /…
Design
Cohort
Follow-up
180 days
Authors
Discussion
Loading...
Member takes
Implication
Multimarker models improve post-discharge risk stratification in high-risk AHF; extends single-biomarker approaches and supports prospective validation for clinical use.
Structured PICO
Does a multimarker, multi-time-point model improve prediction of post-discharge clinical outcomes in high-risk acute heart failure patients?
P
Population
2033 high-risk patients with acute heart failure (AHF) enrolled in the PROTECT trial
I
Intervention
Multimarker model combining blood urea nitrogen (BUN), chloride, interleukin (IL)-6, cTnI, sST-2 and VEGFR-1 measured at multiple time-points (baseline, days 2 or 3, 7, and 14)
C
Comparator
Single biomarkers at single time-points / baseline clinical model
O
Outcome
30-day all-cause mortality, 30-day death or rehospitalization for renal/cardiovascular causes, and 180-day all-cause mortalityhard clinical
A multimarker model combining BUN, chloride, IL-6, cTnI, sST-2, and VEGFR-1 significantly improves risk prediction for mortality in acute heart failure compared to single biomarkers.
Cite This Study
Demissei et al. (2015) studied this question.